Tag: vaccines

Are There Clear and Consistent Racial Differences in Immunity?

So, the short answer is “Probably not.” I did a little digging on this because I heard the recently confirmed HHS Secretary Robert F. Kennedy Jr (RFK Jr) cite studies which he says did indicate there are differences in humoral immunity between Caucasians and African Americans.

Now remember, I’m a retired general hospital psychiatric consultant and my immunology background consists of the standard immunology lecture in medical school. The class I remember most vividly was the one in which the lecturer stopped her lecture abruptly, sighed deeply and looked defeated, probably because she saw the look of confusion on our faces.

Now that you know my credentials, let me just review what I found in a far from exhaustive review of the scientific literature on the topic of whether or not African Americans have, as RFK Jr. remarked, a “better” immune system than Caucasians.

On my own, I found what RFK Jr referred to variously (depending what social media web source you use) as the “Poland” or “pollen” studies as the scientific source of information supporting his view. I suspect it’s this, in which the last author in the citation is GA Poland:

Haralambieva IH, Salk HM, Lambert ND, Ovsyannikova IG, Kennedy RB, Warner ND, Pankratz VS, Poland GA. Associations between race, sex and immune response variations to rubella vaccination in two independent cohorts. Vaccine. 2014 Apr 7;32(17):1946-53. doi: 10.1016/j.vaccine.2014.01.090. Epub 2014 Feb 13. PMID: 24530932; PMCID: PMC3980440.

It was later in the day that I finally also found the NPR news story, the author of which pointed out the same article.

I also found a couple of other articles which tend to contradict the findings of the Poland et al study. One of them was published in eClinicalMedicine in 2023:

Martin CA, Nazareth J, Jarkhi A, Pan D, Das M, Logan N, Scott S, Bryant L, Abeywickrama N, Adeoye O, Ahmed A, Asif A, Bandi S, George N, Gohar M, Gray LJ, Kaszuba R, Mangwani J, Martin M, Moorthy A, Renals V, Teece L, Vail D, Khunti K, Moss P, Tattersall A, Hallis B, Otter AD, Rowe C, Willett BJ, Haldar P, Cooper A, Pareek M. Ethnic differences in cellular and humoral immune responses to SARS-CoV-2 vaccination in UK healthcare workers: a cross-sectional analysis. EClinicalMedicine. 2023 Apr;58:101926. doi: 10.1016/j.eclinm.2023.101926. Epub 2023 Apr 4. PMID: 37034357; PMCID: PMC10071048.

The list of references include the Poland study (reference 27) cited above. The bottom line is the African American immune response to Covid is not “better” than that of white health care workers but the Asian immune response was stronger. I thought it was interesting that in the section “Evidence before this study,” the authors point out that in one previous study, African Americans had lower antibody responses to vaccination than Whites.

I looked at only one other study, published in Clinical Microbiology Review in 2019;

Zimmermann P, Curtis N2019.Factors That Influence the Immune Response to Vaccination. Clin Microbiol Rev 32:10.1128/cmr.00084-18.https://doi.org/10.1128/cmr.00084-18

OK, so I didn’t hunt through all 582 references, but I thought it was enough to note that the authors didn’t mention race as even being relevant anywhere in the body of the paper.

That said, I suspect the more important fact to focus on is racial disparity regarding African Americans even getting vaccines, especially the Covid vaccine. Vaccine hesitancy is common in this population and probably more important to address rather than whether or not there are significant racial differences in immunogenicity. The major challenge is providing accurate information about vaccines in general and Covid vaccines in particular.

The CDC Advisory Committee includes African American members who attend each meeting and emphasize the importance of including black people in vaccination campaigns. OK, so why was the meeting this month cancelled, postponed, or whatever?

Hey, I’m just an old psychiatrist, so don’t take my word for it about anything here. Ask an immunologist. If the immunologist gives you a blank look, you could try a Ouija Board.

CDC Healthcare Provider Toolkit

The CDC has a healhcare provider toolkit available to prepare their patients for the 2023 for the fall and winter virus season. It’s up to date and comprehensive.

CDC Issues Health Alert Network Announcement Recommending Vaccinations for Seasonal Respiratory Illnesses

The CDC recently issued a Health Alert Network (HAN) announcement urging physicians to recommend that patients get their influenza, Covid-19, and RSV vaccines.

What’s Up with Intranasal Covid-19 Vaccines?

I saw the JAMA article on intranasal vaccines research for Covid-19. It starts off pretty supportive of the principle. However, at the bottom of the article, the outlook looks pretty stable for injectable vaccines for at least a good long while.

It’s an interesting read. Skip to the Many Questions section:

How these experimental mucosal vaccines stack up against mRNA vaccines, considered the standard of care, remains to be seen, Beigel noted. The NIAID intends to conduct phase 2 trials that would compare mucosal and mRNA vaccines head-to-head, “so you’d know for certain what you’re trading off,” he said.

Ideally, a mucosal vaccine would generate as good a systemic immune response as an mRNA vaccine as well as a robust mucosal immune response. But an excellent mucosal immune response might make up for a bit of a decline in the systemic immune response, Beigel explained. Perhaps a vaccine inhaled through the mouth and into the lungs could provide the best of both worlds—strong mucosal and systemic immunity—but there are no data yet to support that theory, he said.

“Everyone knows we need a better vaccine and would really like it if we could get something that interrupts transmission and stops even mild disease,” Beigel said. “Whether that’s attainable or not, we don’t know.”

I’m not knocking the concept by suggesting you read the Conflict of Interest Disclosures.

Reference:

Rubin R. Up the Nose and Down the Windpipe May Be the Path to New and Improved COVID-19 Vaccines. JAMA. Published online December 06, 2023. doi:10.1001/jama.2023.0644

Update on CDC Recommendation for Adult RSV Vaccination

I just checked to see if the Iowa Board of Pharmacy rules had changed about the recommendation that a physician and patient shared decision-making discussion should help clarify whether and why a prescription would be necessary to enable a patient over the age of 60 years to get the Respiratory Syncytial Virus (RSV) vaccine.

I found out that nothing has changed the position of the Iowa Board of Pharmacy on this issue, despite the CDC published list which now includes the RSV vaccine (which seemed to be the main issue against allowing pharmacists to administer the vaccine independently). I finally found the CDC Adult Immunization Schedule by Age web page. The section shows a table of vaccines recommendations broken down by age. Below the table is a list of the CDC recommended vaccines. Under the RSV category there is a Special Situation section with guidance for those over the age of 60 regarding those most likely to benefit from the RSV vaccine:

  • “Age 60 years or older: Based on shared clinical decision-making, 1 dose RSV vaccine (Arexvy® or Abrysvo™). Persons most likely to benefit from vaccination are those considered to be at increased risk for severe RSV disease.** For additional information on shared clinical decision-making for RSV in older adults, see www.cdc.gov/vaccines/vpd/rsv/downloads/provider-job-aid-for-older-adults-508.pdf.

For further guidance, see www.cdc.gov/mmwr/volumes/72/wr/mm7229a4.htm

**Note: Adults age 60 years or older who are at increased risk for severe RSV disease include those with chronic medical conditions such as lung diseases (e.g., chronic obstructive pulmonary disease, asthma), cardiovascular diseases (e.g., congestive heart failure, coronary artery disease), neurologic or neuromuscular conditions, kidney disorders, liver disorders, hematologic disorders, diabetes mellitus, and moderate or severe immune compromise (either attributable to a medical condition or receipt of immunosuppressive medications or treatment); those who are considered to be frail; those of advanced age; those who reside in nursing homes or other long-term care facilities; and those with other underlying medical conditions or factors that a health care provider determines might increase the risk of severe respiratory disease.”

While the rationale for the recommendation is clear, it’s interesting that Iowa is one of only 4 states in which pharmacists cannot administer the RSV vaccine independently (meaning a physician prescription is necessary). The RSV vaccine is in the CDC published vaccination schedule, which looks like it would satisfy the Iowa Code Section 155A.46 according to the Iowa Board of Pharmacy.

I still wonder whether it’s the shared decision-making discussion or the Iowa Code that’s the main reason a physician prescription is necessary to get the RSV vaccine.

It isn’t that I want the RSV vaccine. In fact, based on what I’ve read on the CDC Immunization Schedule, I don’t think I need it because I’m pretty healthy for a geezer. I just don’t understand why only 4 states require a physician prescription. Does that mean the pharmacists in the rest of the country are confident they can have a shared decision-making discussion with patients about the indication for the RSV vaccine?

Covid-19 and Flu Vaccines Today

Today I got the new Covid-19 vaccine and the flu shot. I scheduled on line late last week and got right in. I didn’t have to wait long in line—and there were others getting the same vaccines. Sena will get them tomorrow.

It’s up to you.

What’s Up with Shared Clinical Decision Making for the RSV Vaccine?

There are probably some questions about the new Respiratory Syncitial Virus (RSV) vaccine. Because I’ve seen TV commercials about the new website RSVandMe, I checked on a few things the other day.

The RSVandMe website and the companion website are both produced by the RSV vaccine maker GlaxoSmithKline (GSK). As such, I consider them marketing commercials.

I checked the Centers for Disease Control (CDC) website and saw that the CDC Advisory Committee on Immunization Practices (ACIP) recommended approval of the RSV vaccine at their June Meeting (covered earlier on this blog):

Adults 60 years of age and older may receive a single dose of Respiratory Syncytial Virus (RSV) vaccine, using shared clinical decision-making.

The term “shared clinical decision-making” is clarified on the CDC webpage at this link.

The upshot of shared clinical decision-making is that it’s up to the provider (the list of providers include pharmacists). So far the list of recommended vaccines does not yet include RSV, so it probably needs updating. It looks like the ACIP MMWR recommendation page also needs updating.

Brief Remarks on CDC ACIP Vaccines Meeting This Week

My impressions of the first couple of days of the CDC ACIP meeting on vaccines will be brief. My wife and I were interested in learning more about the new Respiratory Syncytial Virus (RSV) vaccine. It sounds like the vaccine was upvoted with only a few no votes. Most committee members thought the vaccine was a good idea. It sounds like the decision to get the RSV vaccine should be in the context of a shared-decision making conversation with your doctor.

We didn’t get a chance to hear the presentation on the Polio vaccine. The slides were available and it looks like most people are vaccinated. The recommendation is that if you’re not already vaccinated or incompletely vaccinated, or you’re a health care worker likely to encounter patients with polio, a laboratory worker who might handle material with the polio virus in it, or traveling to regions where you might contract it, then the vaccine would be recommended.

Here is a link to the presentation slides.

CDC ACIP Meeting Today on Vaccines

The ACIP meeting on several vaccines begins today and runs through Friday, 8:00 a.m-5:30 p.m. on the 21st-22nd and 8:00 a.m.-12:40 p.m. on the 23rd, ET.

The committee will discuss vaccines for Respiratory Syncytial Virus in adults, Polio, and Influenza vaccines on the 21st. There will be a vote for each.

They will discuss vaccines for Pneumococcal, Dengue, Chikungunya, Respiratory Syncytial Virus (pediatric and maternal) on the 22nd. They will vote on the pneumococcal vaccine.

They will discuss Mpox, Meningococcal, and Covid-19 vaccines on the 23rd.

Four Seasonal Vaccines for Older Adults?

There are a number of seasonal vaccines recommended for older adults in the U.S. They include vaccines for influenza, pneumonia, and the newest one is Respiratory Syncytial Virus (RSV).

I noticed that during the recent FDA meeting to decide on approval of another vaccine for the XBB variant of Covid-19, many experts objected to the use of the word “periodic” in the voting question.

Those objecting to it did so because of the implicit suggestion that Covid-19 is a seasonal virus. Not all experts agree on that. I gather it takes time to determine whether or not an infectious agent should be considered seasonal or not.

If the XBB variant of Covid-19, RSV, pneumonia, and influenza are all considered seasonal, then there are 4 vaccines for which older adults would be eligible.

The consensus among most experts is that you can take both influenza and Covid-19 vaccines at the same time. Most of us older adults also get the pnemococcal vaccine as well.

Will the RSV vaccine be added to the list? Should you get all 4 at the same time? Or should they be spaced out? Should you get the influenza and Covid-19 vaccines together and wait a week or two before getting the RSV and pneumococcal vaccines?

The increase in recommendations for vaccinations could be burdensome for those without health insurance. Vaccine uptake will probably continue to be a challenge.